3
Announcements
Trials
Browse
Landscape
Status
Recruiting
2
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Observational
3
Interventional
1
Sponsor
Cancer Type
Genitourinary
3
Conditions
Breast Neoplasms
468
Neoplasms
316
Carcinoma, Non-Small-Cell Lung
269
Prostatic Neoplasms
215
Colorectal Neoplasms
208
Lung Neoplasms
178
Multiple Myeloma
123
Melanoma
110
Carcinoma, Renal Cell
107
Ovarian Neoplasms
94
Carcinoma, Hepatocellular
78
Pancreatic Neoplasms
69
Urinary Bladder Neoplasms
65
Stomach Neoplasms
64
Neoplasm Metastasis
64
Leukemia, Lymphocytic, Chronic, B-Cell
62
Colonic Neoplasms
60
Leukemia, Myeloid, Acute
53
Uterine Cervical Neoplasms
50
Recurrence
49
Liver Neoplasms
46
Lymphoma, Follicular
45
Lymphoma
45
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
39
Esophageal Neoplasms
37
Precursor Cell Lymphoblastic Leukemia-Lymphoma
36
Lymphoma, Large B-Cell, Diffuse
35
Hematologic Neoplasms
35
Head and Neck Neoplasms
35
Lymphoma, Non-Hodgkin
34
Interventions
darolutamide
2
Docetaxel
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
Observational
×
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
×
Clear all
NCT07395804
2026-05-29
23146
Bayer
Recruiting
500 enrolled
NCT06661122
2026-05-19
HAYATE
Bayer
Recruiting
100 enrolled
NCT06010914
2026-04-15
DADOX
Bayer
Active not recruiting
100 enrolled